Contemporary management of metastatic breast cancer has evolved toward tumor biology-guided systemic therapy selection. Adherence to updated NCCN Guidelines has demonstrably improved survival outcomes, reflecting the integration of novel targeted agents and refined treatment algorithms into standard oncologic care.